Hoffmann-La Roche: Multiple Sclerosis trials
The registry lists 35 Multiple Sclerosis studies with Hoffmann-La Roche as lead sponsor. 6 are open to participants now and 11 have results posted.
Phase 1 6Phase 2 7Phase 3 12Phase 4 6No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants With Multiple Sclerosis (MS)Not yet recruitingNCT07937852Phase 3
- A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple SclerosisNot yet recruitingNCT07749157Phase 1
- A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 TherapyRecruitingNCT07609719Phase 4
- A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)RecruitingNCT07161258Phase 2
- A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)RecruitingNCT06780150
- An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab TreatmentRecruitingNCT06675955Phase 3
- A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)Active, not recruitingNCT05119569Phase 2Results posted
- A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving OcrelizumabCompletedNCT04998851Phase 4Results posted
- A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During PregnancyCompletedNCT04998812Phase 4Results posted
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)Active, not recruitingNCT04548999Phase 3Results posted
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)Active, not recruitingNCT04544436Phase 3Results posted
- A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple SclerosisActive, not recruitingNCT04075266Phase 2Results posted
- A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)CompletedNCT03606460Phase 3Results posted
- This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)CompletedNCT03599245Phase 3Results posted
- A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple SclerosisCompletedNCT01412333Phase 3Results posted
- A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple SclerosisCompletedNCT01247324Phase 3Results posted
- A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple SclerosisCompletedNCT00087529Phase 2/3Results posted
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple SclerosisActive, not recruitingNCT07667322Phase 1
- A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)Active, not recruitingNCT07074886Phase 2
- A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple SclerosisActive, not recruitingNCT07008378Phase 1
- Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple SclerosisSuspendedNCT05949580
- A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple SclerosisActive, not recruitingNCT05704361Phase 1
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple SclerosisActive, not recruitingNCT05269004Phase 3
- A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple SclerosisWithdrawnNCT05208840Phase 4
- Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)Active, not recruitingNCT04586023Phase 3
- A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)Active, not recruitingNCT04586010Phase 3
- Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With OcrelizumabCompletedNCT04377555Phase 4
- A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple SclerosisCompletedNCT03972306Phase 1
- Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple SclerosisCompletedNCT03593590
- A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic SettingCompletedNCT03589105Phase 4
- Monitoring of Multiple Sclerosis (MS) Participants With the Use of Digital Technology (Smartphones and Smartwatches) - A Feasibility StudyCompletedNCT02952911Not applicable
- Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple SclerosisNo longer availableNCT02807285
- Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.CompletedNCT01808885Phase 1
- A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.WithdrawnNCT00104143Phase 2
- A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple SclerosisCompletedNCT00097188Phase 2